| Identification | Back Directory | [Name]
RLY-4008 HCl | [CAS]
2688040-45-9 | [Synonyms]
RLY-4008 HCl
FGFR2-IN-3 hydrochloride
lirafugratinib (RLY4008)
Lirafugratinib Hydrochloride | [Molecular Formula]
C28H25ClFN7O2 | [MOL File]
2688040-45-9.mol | [Molecular Weight]
546 |
| Hazard Information | Back Directory | [Uses]
Lirafugratinib (RLY-4008) hydrochloride is an orally active, irreversible and highly selective FGFR2 inhibitor with an IC50 of 3 nM. Lirafugratinib hydrochloride covalently binds to Cys491. Lirafugratinib hydrochloride targets FGFR2 primary alterations and resistance mutations and induces tumor regression while sparing other FGFRs[1]. | [in vivo]
Lirafugratinib (RLY-4008; 1-30 mg/kg; orally, twice daily; 15-30 days) hydrochloride demonstrates antitumor activity in FGFR2-altered cancer xenograft models[1].
| Animal Model: | Female BALB/c nude mice with SNU-16 and AN3CA xenografts; female NOD SCID mice with CC13-7 and ICC13-7-FGFR2V564F xenografts[1] | | Dosage: | 1, 3, 10, 30 mg/kg | | Administration: | Orally; twice daily; for 15-30 days | | Result: | Exhibited dose-dependent antitumor activity and induced tumor regression in all models.
|
| [IC 50]
FGFR2: 3 nM (IC50) | [References]
[1] Vivek Subbiah, et al. RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations. Cancer Discov. 2023 Sep 6;13(9):2012-2031. DOI:10.1158/2159-8290.CD-23-0475 |
|
|